ImpediMed’s corporate governance encompasses Board Committees and Board Charters, Company Constitution, and Governance Policies.
Corporate Governance StatementThe purpose of this charter is to specify how ImpediMed is governed so as to promote the Company and protect the interests of shareholders. The Board is responsible for the corporate governance of ImpediMed. This Charter sets out the roles and responsibilities of the Board, which responsibilities are delegated to committees of the Board or to management, the framework for the operation of the Board, as well as the membership of the Board.
The Annual General Meeting of ImpediMed Limited (ImpediMed or Company) was held on Tuesday, November 19th commending at 11.00am (AEDT) at the offices of Clifford Chance, Level 24, Brookfield Place, 10 Carrington Street, Sydney NSW 2000, and via an audio webcast.
As a key component of ImpediMed’s corporate governance regime, the Board has established the following subcommittees.
The role of this committee is to ensure that the Board comprises suitably qualified and experienced individuals to act as Directors. The committee does so through its review of the composition of the Board and the tenure of the Directors. This committee will also conduct annual assessments of the performance of individual Directors.
View
This committee is responsible for monitoring the current and emerging risks affecting the Company and overseeing the risk mitigation activities. In fulfilling its responsibilities, the committee provides advice on the integrity of the Company’s financial reporting process and financial statements, the Company’s compliance with legal and regulatory requirements, the independence of effectiveness of external auditors, and the effective maintenance of internal controls.
View
This committee is responsible for setting and overseeing the application of the Company’s remuneration structure and policy. In performing this role, the committee reviews the performance and remuneration of staff and assesses whether appropriate incentives are provided for management and employees.
View
| Director | Date Appointed |
Executive / Non-Executive |
Independent Director | Audit & Risk Management Committee |
Remuneration Committee |
Nomination Committee |
|---|---|---|---|---|---|---|
| Christine Emmanuel-Donnelly | September 2023 | Non-Executive, Chair | Yes | Member | Chair | Chair |
| Parmjot Bains | January 2024 | Managing Director & CEO | No | – | – | – |
| Janelle Delaney | September 2023 | Non-Executive | Yes | Member | Member | Member |
| Andrew Grant | September 2023 | Non-Executive Director | No | Member | Member | Member |
| McGregor Grant | September 2023 | Executive Director & CFO | No | – | – | – |
| Fiona Bones | June 2024 | Non-Executive Director | Yes | Chair | – | Member |
ImpediMed will disclose on this website any amendments that we make to, or waivers that we grant from our Governance Policies affecting our principal executive officers, principal financial officer and principal accounting officer or controller, or persons performing similar functions that relate to deterring wrongdoing or promoting: